BC Platforms is involved in major EU-funded projects and is applying for further grant applications for public-private consortia
ONCOVALUE
Value-based oncology care
ONCOVALUE is an EU-funded, AI-driven, cancer data initiative. This collaborative effort aims to develop novel AI-based tools to automate the collection and analytics of clinical data, assessing in real-time, real-life effectiveness of novel cancer therapies. This will support the development of effective medicines, reduce spending on drugs that yield little benefit and enable oncologists to promote value-based cancer care.
The ONCOVALUE consortium is made up of eleven institutions and companies in Finland, The Netherlands, Denmark, Portugal, and Italy. Over the four-year project span, annually around 40,000 European patients will participate from hospitals in the consortium.
BC Platforms will assist in developing an advanced data infrastructure capable of securely integrating, harmonizing and analyzing large-scale cancer datasets from across Europe, and transforming unstructured patient data into structured data and real-world evidence that clinicians can use.
-
- Implementing federated infrastructure for RWD reporting in health regulatory and HTA decision making
- Assist in developing an advanced data infrastructure capable of securely integrating, harmonizing and analyzing large-scale cancer datasets from across Europe
- Implement federated data network platform and provide open application programming interface (API) for accessing the data network
- Implement data analysis and reporting tools for RWD reporting in real-time
Learn more: Poster published at OHDSI Europe Symposium in May 2024
ARTEMIs
AcceleRating the Translation of virtual twins towards a pErsonalized Management of fatty lIver patients
ARTEMIs is a four-year research project, aiming to co-design and develop a POC of a Clinical Decision Support System (CDSS)— a cutting-edge clinical visualization tool— offering an overview of patient multimodal data and therapeutic decision-aid, thanks to the integrated virtual twin models. The CDSS provides dynamic and multilevel representations of tissues and organs and will provide support to clinicians to achieve early diagnosis, prediction of disease evolution, assessment of cardiovascular outcomes, and guidance towards specific treatments or interventions. This will mark a significant leap forward in MAFLD patient’s healthcare
Medexprim, member of BC Platforms Group, is the architect and a proud participant of ARTEMIs.
This project has received funding from the European Union within the Horizon Europe program under grant agreement N° 101136299.
Learn more about ARTEMIs.
-
- 7500 patients
- 21 partners
- €10M funding
- 9 countries
-
Access the ARTEMIs brochure by completing this form:
EUCAIM
Accelerating Innovations In Cancer Diagnosis And Treatment
EUCAIM, the first-of-its-kind European pan-cancer infrastructure, is a four-year research project, aiming to deploy a pan-European digital federated infrastructure of FAIR cancer-related de-identified images from Real-World Data. The infrastructure, called Cancer Image Europe, is designed to preserve the data sovereignty of providers, and provide a platform, including an Atlas of Cancer Images, for the development and benchmarking of AI tools towards Precision Medicine. It targets clinicians, researchers, and innovators, to give the means to build up validated clinical decision-making systems supporting diagnosis, treatment, and predictive medicine to benefit patients.
Medexprim, member of BC Platforms Group, is a proud participant of EUCAIM.
This project has received funding from the European Union under grant agreement No 101100633.
Learn more about EUCAIM.
-
- 6 cancers
- 76 partners
- 14 countries
- €18M funding
CHAIMELEON
Accelerating the lab to market transition of AI tools for cancer management
CHAIMELEON is a four-year research project setting up a EU-wide structured repository for health imaging data to be openly reused in AI experimentation, with the creation of four datalakes for four cancers: lung, breast, colorectal, prostate. The repository is designed to meet the need for access to large datasets of high quality in interoperable repositories enabling secure sharing across Europe with the specific purpose of constituting an open, accessible, intuitive resource for the community of developers of AI-based solutions for cancer management.
Medexprim, member of BC Platforms Group, is the technical leader of CHAIMELEON.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 952172.
Learn more about CHAIMELEON.
-
- 4 cancers
-
18 partners
-
9 countries
-
€8.8M funding